List of Excipients in Branded Drug FOSRENOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	FOSRENOL	lanthanum carbonate	54092-252	DEXTRATES
Takeda Pharmaceuticals America Inc	FOSRENOL	lanthanum carbonate	54092-252	MAGNESIUM STEARATE
Takeda Pharmaceuticals America Inc	FOSRENOL	lanthanum carbonate	54092-252	SILICON DIOXIDE

FOSRENOL Excipient Strategy and Commercial Opportunities for Lanthanum Carbonate

Last updated: August 16, 2026

FOSRENOL is a lanthanum carbonate phosphate binder used to control serum phosphate in patients with end-stage renal disease. Its commercial opportunity is concentrated in formulation improvement rather than active-ingredient differentiation. The main value drivers are dose burden, palatability, powder handling, gastrointestinal tolerability, pediatric usability, manufacturing efficiency, and access to generic and specialty-pharmacy channels.

The original FOSRENOL product has two relevant dosage-form strategies: flavored chewable tablets and oral powder. The formulation platform creates opportunities for lower-cost generic products, improved taste-masked products, unit-dose powders, pediatric-oriented presentations, and differentiated binders that reduce administration burden. The principal constraints are the high gram-level dose, the need to administer the product with or immediately after meals, lanthanum-related taste and mouthfeel, and the requirement to demonstrate pharmaceutical equivalence and bioequivalence through an FDA-acceptable abbreviated new drug application pathway.

What is FOSRENOL and how does the product work?

FOSRENOL contains lanthanum carbonate, a non-calcium phosphate binder. In the gastrointestinal tract, lanthanum binds dietary phosphate and reduces phosphate absorption. The drug is not intended to be swallowed whole as a conventional immediate-release tablet. The chewable tablets must be thoroughly chewed before swallowing, while the oral powder is mixed with a soft food and consumed with or immediately after a meal [1].

Product characteristic	FOSRENOL profile
Active ingredient	Lanthanum carbonate hydrate
Therapeutic class	Non-calcium phosphate binder
Primary indication	Reduction of serum phosphate in patients with end-stage renal disease
Administration	With or immediately after meals
Dosage forms	Chewable tablets; oral powder
Tablet strengths	500 mg, 750 mg, 1,000 mg lanthanum carbonate
Powder strength	750 mg and 1,000 mg sachets
Primary formulation challenge	High dose, taste, chewability, powder dispersion, gastrointestinal tolerability
Regulatory route for generics	Generally ANDA-based, subject to FDA product-specific requirements

The drug’s mechanism creates an important formulation distinction. Systemic exposure is not the principal driver of efficacy. The product acts locally in the gastrointestinal tract. That can give developers more flexibility to optimize excipients for taste, texture, dispersion, and dose delivery, provided the finished product retains equivalent phosphate-binding performance and meets applicable quality standards.

What excipients are used in FOSRENOL formulations?

The marketed dosage forms use relatively simple excipient systems. The specific composition differs by presentation.

FOSRENOL chewable tablets

The FDA label identifies excipients including colloidal silicon dioxide, dextrates, and magnesium stearate [1]. The formulation is designed to produce a chewable product rather than a conventional tablet intended for rapid disintegration in water.

The functional roles are generally:

Excipient category	Likely formulation function
Dextrates or carbohydrate-based filler	Bulk, compressibility, chewable texture, sweetness contribution
Colloidal silicon dioxide	Flow aid, moisture control, processability
Magnesium stearate	Lubrication during compression
Flavor system	Masking of lanthanum-related taste and chalky mouthfeel
Sweetener system	Palatability and patient acceptance

The label-specific excipient list should control any product-development or patent analysis. A generic developer cannot assume that a formulation with the same inactive ingredients is required. FDA approval generally turns on pharmaceutical equivalence, product performance, labeling, and applicable bioequivalence requirements, not literal duplication of every excipient.

FOSRENOL oral powder

The oral powder contains lanthanum carbonate hydrate and maltodextrin, according to the product labeling [1]. Maltodextrin supplies bulk and can improve powder handling and dispersion in soft foods. The powder is intended to be mixed before administration, so the product must distribute adequately through the food vehicle without excessive agglomeration, sedimentation, or unpleasant mouthfeel.

The oral powder presentation has a different commercial logic from the tablet. It is better suited to patients who have difficulty chewing tablets, patients requiring flexible administration, and caregivers who prefer unit-dose sachets. It also creates development opportunities involving particle engineering, sachet packaging, moisture protection, food compatibility, and flavor systems.

Which excipient strategies are most commercially attractive?

The strongest opportunities involve improvements that reduce administration friction without changing lanthanum carbonate’s local mechanism.

Taste masking and mouthfeel control

Lanthanum carbonate products can present metallic, mineral, chalky, or otherwise undesirable sensory attributes. Taste masking is therefore a central excipient opportunity.

Potential approaches include:

• High-intensity sweeteners combined with bulk sweeteners.
• Fruit, citrus, vanilla, or neutral flavor systems.
• Polymer-based taste-masking coatings on lanthanum particles.
• Lipid or wax barriers that reduce immediate tongue contact.
• Ion-exchange or adsorption systems.
• Granulation that reduces free surface area.
• Flavor-on-dose systems for sachets or sprinkle products.

A formulation that merely increases sweetness may fail if it leaves a gritty or chalky residue. Sensory development should assess aftertaste, particle perception, grittiness, saliva interaction, and the impact of mixing into common soft foods.

Chewable-tablet texture

The tablet must be strong enough to withstand packaging and transport but easy to chew. Excessive hardness increases administration difficulty. Excessive friability creates powder loss, dose variability, and poor consumer handling.

Useful formulation levers include:

• Direct-compression carbohydrate fillers.
• Polyols for a softer chew.
• Controlled granulation to improve content uniformity.
• Porous excipient structures to reduce tablet density.
• Low-level disintegrants where they improve breakup after chewing.
• Lubricant optimization to avoid slowed wetting or poor compaction.

A softer tablet may improve patient acceptance but can increase friability and moisture sensitivity. A more porous tablet may improve chewability but create larger tablets at an already high dose. The commercial target is a robust tablet with low fracture force and limited residual grit.

Powder dispersion and food compatibility

The oral powder must be easy to mix with soft food and consume promptly. The product should avoid:

• Visible clumping.
• Rapid settling.
• Excessive dusting.
• Strong odor or flavor release.
• Localized high-concentration pockets.
• Texture changes in applesauce, yogurt, puree, or similar food vehicles.

Excipient strategies include particle-size control, agglomeration, flow enhancers, low-moisture carriers, and flavors compatible with multiple food matrices. A product optimized only for one food vehicle may have poor real-world usability.

Dose-burden reduction

Lanthanum carbonate is administered in gram-level quantities. The tablet strengths are 500 mg, 750 mg, and 1,000 mg, and patients may require multiple tablets per meal depending on serum phosphate and dietary intake [1]. Dose burden is a commercial weakness relative to products that can achieve phosphate binding with fewer or smaller units.

Excipient development can improve swallowability and tablet size, but it cannot remove the mass of the active ingredient. The most credible strategies are:

• Higher drug loading through improved granulation and compression.
• Lower-density excipient systems that preserve tablet dimensions.
• Multi-unit powder presentations.
• Sachets that simplify repeated dosing.
• More palatable products that improve adherence even when dose count remains high.

Claims that a new excipient system materially reduces required lanthanum dose would face a higher evidentiary burden because dose is tied to phosphate intake and clinical response.

What formulation patents protect FOSRENOL and lanthanum carbonate products?

The core commercial protection for FOSRENOL was based primarily on active-ingredient and pharmaceutical-composition patents rather than a broad, durable excipient moat. Historic patent protection for lanthanum carbonate products included U.S. patents associated with the development and use of lanthanum carbonate as a phosphate binder. Key core patents expired or reached the end of their relevant terms before the current generic market matured.

Current formulation opportunities are more likely to rely on new, narrow patent claims covering:

• Specific taste-masking coatings.
• Particle-size distributions.
• Granulated lanthanum carbonate compositions.
• Moisture-controlled powder systems.
• Sachet packaging and dispersion systems.
• Specific sweetener-flavor combinations.
• Chewable tablets with defined hardness, friability, and disintegration properties.
• Pediatric administration methods.
• Combination products with other phosphate-binding agents.

A new formulation patent must provide more than a substitution of one conventional filler for another. The strongest claims would link the excipient system to a measurable technical result, such as reduced bitterness, reduced gritty mouthfeel, improved dispersion, reduced moisture uptake, improved content uniformity, or improved tablet mechanical performance.

What is the Orange Book status of FOSRENOL?

FOSRENOL’s historic exclusivity was based on FDA approval and patent protection that has largely elapsed. The practical generic strategy is therefore an ANDA for a pharmaceutically equivalent lanthanum carbonate product, subject to current FDA requirements and any remaining listed patent or exclusivity rights reflected in the Orange Book.

The Orange Book should be checked for the current product-specific listing, patent data, therapeutic-equivalence codes, and any active reference-product exclusivity. Patent status can change through delisting, expiration, pediatric extensions, or regulatory updates. A commercial decision should use the current FDA Orange Book record rather than historical patent summaries [2].

When did FOSRENOL lose exclusivity and when can generics launch?

FOSRENOL was approved by FDA in 2004. The original product received orphan-drug exclusivity associated with its initial indication, but that exclusivity does not create a permanent barrier to generic entry. Generic lanthanum carbonate products have entered the U.S. market, confirming that the principal market barrier is no longer an unexpired core exclusivity right.

Milestone	Commercial significance
2004 FDA approval	Established FOSRENOL as a phosphate-binder product
Initial orphan exclusivity period	Temporarily limited approval of competing products for the protected indication
Expiration of core patent protection	Opened the principal pathway for generic competition
Generic ANDA approvals	Shifted competition toward price, supply reliability, formulation usability, and channel access
Current market	Brand and generic products compete primarily on contracting, availability, dosage form, and patient acceptance

Paragraph IV risk is now most relevant to any remaining listed patents covering a particular dosage form, formulation, or use. A developer should not assume that a generic filing is risk-free merely because the original composition patent has expired. A product-specific patent could still require certification and trigger litigation. Conversely, a Paragraph IV challenge may have limited commercial value if the challenged patent does not materially delay approval or if several generic manufacturers are already approved.

Which companies are challenging or competing with FOSRENOL?

The competitive landscape includes generic lanthanum carbonate manufacturers and branded phosphate-binder companies.

Generic lanthanum carbonate competitors

Generic entrants compete on:

• Tablet and powder availability.
• Manufacturing cost.
• Wholesale acquisition price.
• Group purchasing organization contracts.
• Pharmacy substitution.
• Supply continuity.
• Packaging and unit-dose convenience.

The relevant competitors are not limited to companies with identical brand positioning. Generic lanthanum carbonate competes with sevelamer carbonate, sevelamer hydrochloride, calcium acetate, sucroferric oxyhydroxide, and ferric citrate. These products differ in pill burden, tolerability, metal content, cost, and prescribing patterns.

Branded phosphate binders

Product	Active ingredient	Commercial differentiation
FOSRENOL	Lanthanum carbonate	Non-calcium binder; chewable tablet and powder options
Renvela/Renagel	Sevelamer carbonate/hydrochloride	Non-calcium polymer binder; broad dialysis use
Velphoro	Sucroferric oxyhydroxide	Chewable iron-based binder; lower tablet burden positioning
Auryxia	Ferric citrate	Iron-based binder with iron-repletion attributes
Calcium acetate products	Calcium acetate	Low-cost calcium-based phosphate binding

FOSRENOL’s most defensible commercial position is patient-specific tolerability and dosage-form preference. Its weakest position is price once generic lanthanum carbonate products are available.

What generic launch scenarios exist for lanthanum carbonate?

Scenario 1: Low-cost tablet substitution

This is the most direct strategy. The developer matches the reference product’s dosage form and strengths, uses conventional excipients, and competes through manufacturing cost and distribution.

The advantages are a simpler commercial proposition and lower formulation risk. The disadvantages are limited differentiation and rapid price erosion.

Scenario 2: Premium taste-masked chewable tablet

A developer can pursue a more palatable tablet with improved flavor, reduced grit, or better chewability. The product may support a differentiated label or branded-generic strategy if the sensory improvement is meaningful and legally protectable.

The key risk is that payers may not reimburse a premium unless the product improves adherence, reduces switching, or addresses a documented administration problem.

Scenario 3: Unit-dose oral powder

A sachet-based powder can target patients who cannot chew tablets or who prefer administration with soft food. This presentation may be particularly relevant in institutional care, home dialysis support, and caregiver-managed medication administration.

The commercial barriers are packaging cost, moisture control, food-mixing instructions, and the need to establish acceptable product performance.

Scenario 4: Pediatric or dysphagia-focused product

The oral powder and soft chewable formats can support populations with swallowing limitations. The opportunity depends on the approved age range, clinical demand, and the extent to which the product can be differentiated without triggering additional clinical or regulatory requirements.

Scenario 5: Combination phosphate-binder product

Combining lanthanum with another binder could reduce pill burden or broaden phosphate-binding capacity. This strategy would require careful clinical, regulatory, and intellectual-property analysis. It is less attractive as a straightforward generic opportunity because the product may move beyond conventional ANDA equivalence.

How strong is the FOSRENOL patent estate?

The core FOSRENOL patent estate is weaker today than during the product’s launch period because the principal composition and use protections have expired or become commercially less restrictive. The stronger patent opportunity now lies in follow-on formulations rather than the original lanthanum carbonate concept.

Patent category	Current strategic value
Core lanthanum carbonate composition	Low after expiration
Broad phosphate-binding method claims	Low to moderate, depending on jurisdiction and claim scope
Chewable-tablet formulation	Moderate if claims cover defined performance or composition
Oral powder formulation	Moderate, especially for dispersion, moisture, and packaging
Taste-masking technology	Moderate to high if supported by comparative sensory data
Pediatric administration claims	Moderate, subject to regulatory and obviousness analysis
Manufacturing process	Moderate where it improves loading, uniformity, or impurity control
Packaging and stability	Moderate for moisture-sensitive unit-dose products

Patent strength should be assessed claim by claim. A formulation patent with narrow excipient percentages and no demonstrated technical effect may have limited blocking power. A patent that ties a defined composition to measurable sensory or stability improvements can support stronger licensing or branded-generic economics.

What manufacturing and intellectual-property barriers affect new products?

Lanthanum carbonate development has several CMC issues despite the absence of a complex biologic manufacturing process.

Active-material handling

The active ingredient is used at high dose, making particle-size distribution, bulk density, flow, and content uniformity commercially important. Poor flow can produce weight variation and compression problems. High drug loading can limit the amount of excipient available for taste masking and mechanical optimization.

Moisture and stability

Powder products require protection from moisture and humidity-driven agglomeration. Sachet film selection, seal integrity, desiccant strategy, and stability testing can materially affect cost.

Sensory consistency

Flavor performance may vary with active-particle surface area, storage time, food vehicle, and saliva exposure. Sensory testing should be performed on aged product, not only fresh development batches.

Process patents

A process that produces a unique granule structure, coated particle, or low-dust powder may create an IP position. Process patents are most useful when the manufacturing method is difficult to reverse engineer or when it produces a product attribute that competitors cannot easily reproduce.

What is the FDA regulatory status of FOSRENOL and its generic products?

FDA approved FOSRENOL as a prescription drug for control of serum phosphate in patients with end-stage renal disease [1]. Generic development generally proceeds through the ANDA pathway, with the reference product used to establish pharmaceutical equivalence and bioequivalence or other product-specific performance requirements.

For a locally acting gastrointestinal product, conventional systemic pharmacokinetic comparison may not fully capture therapeutic equivalence. FDA requirements can therefore place greater emphasis on product quality, sameness of dosage form and strength, dissolution or performance testing, and other product-specific criteria. The FDA’s product-specific guidance and current ANDA review requirements should control development decisions [3].

There is no biosimilar pathway for FOSRENOL. Lanthanum carbonate is a small-molecule inorganic drug, not a biologic. Biosimilar risk is therefore zero in the legal sense, although alternative phosphate binders create therapeutic competition.

What licensing deals and settlement agreements affect FOSRENOL?

FOSRENOL originated as a branded pharmaceutical product and was commercialized through corporate ownership and distribution arrangements involving the product’s developers and later owners. Publicly important commercial control has shifted through corporate transactions, including Shire’s acquisition by Takeda.

No widely recognized current settlement agreement provides a general market-wide barrier to generic lanthanum carbonate. Any individual Paragraph IV settlement, authorized-generic arrangement, supply agreement, or manufacturing license should be reviewed in the FDA approval record, litigation docket, SEC filings, and the parties’ public disclosures before being treated as a market constraint.

The commercial relevance of a settlement depends on three terms:

1. The agreed generic launch date.
2. Any authorized-generic or supply rights.
3. Restrictions on dosage forms, strengths, or competing formulations.

What revenue exposure does FOSRENOL create for manufacturers?

Revenue exposure is concentrated in the phosphate-binder franchise rather than in a broad hospital market. The principal economic variables are:

• Number of dialysis patients treated.
• Average daily tablet or sachet volume.
• Brand-to-generic substitution.
• Rebate intensity.
• Formulary position.
• Patient persistence.
• Manufacturing cost per gram of active ingredient.
• Distribution through dialysis providers, specialty pharmacies, and retail channels.

Brand revenue is vulnerable to generic substitution because the active ingredient and indication are readily identifiable. A branded reformulation can preserve value if it solves a clear administration problem, but it will face reimbursement pressure from low-cost generic tablets.

The most attractive commercial segment is likely a differentiated product with one or more of the following attributes:

• Better taste and reduced grit.
• Lower tablet count through higher loading or optimized administration.
• Easy-to-use single-dose sachets.
• Improved use in patients with dysphagia.
• Reliable supply and lower pharmacy substitution friction.
• Evidence of improved adherence or persistence.

Key Takeaways

• FOSRENOL contains lanthanum carbonate and is marketed as chewable tablets and oral powder.
• The main excipient opportunities are taste masking, mouthfeel control, tablet softness, powder dispersion, moisture protection, and high drug loading.
• Core FOSRENOL exclusivity has largely expired, and generic competition has shifted the market toward price and supply economics.
• There is no biosimilar pathway issue because lanthanum carbonate is not a biologic.
• Follow-on formulation patents are more commercially relevant than expired core composition patents.
• The strongest differentiated opportunities are palatable chewables, unit-dose powders, dysphagia-friendly products, and formulations with improved handling or adherence.
• The principal technical barriers are high dose, active-particle handling, sensory performance, moisture control, and food compatibility.
• A premium reformulation must demonstrate a measurable patient or manufacturing benefit to overcome generic pricing pressure.

FAQs

Can lanthanum carbonate be formulated as a conventional swallowed tablet?

A swallowed tablet could be developed only if it satisfies applicable FDA requirements for pharmaceutical equivalence and performance. FOSRENOL chewable tablets are labeled for thorough chewing, so a conventional swallowable tablet would represent a meaningful dosage-form change.

Which excipient is most important for a FOSRENOL generic?

No single excipient controls product success. The most important system is the combined filler, flavor, sweetener, glidant, lubricant, and granulation platform that delivers acceptable chewability, taste, content uniformity, and stability.

Is a lanthanum carbonate powder more commercially attractive than a chewable tablet?

The powder offers greater differentiation for patients with swallowing or chewing difficulty, but it has higher packaging and stability requirements. The tablet is easier to commercialize as a low-cost generic.

Can a new flavor create patent protection for lanthanum carbonate?

A flavor alone usually provides a weak patent position. Stronger protection requires a defined formulation linked to a demonstrated technical result, such as reduced bitterness, improved sensory persistence, or better stability.

Does FOSRENOL compete directly with Velphoro and Auryxia?

Yes. All three are prescription phosphate binders used in dialysis-related hyperphosphatemia, but they use different active ingredients and have different pill-burden, tolerability, iron-related, calcium-related, and reimbursement profiles.

References

1. U.S. Food and Drug Administration. (2023). FOSRENOL (lanthanum carbonate) chewable tablets and oral powder: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development.
4. DailyMed. (2024). FOSRENOL: Lanthanum carbonate prescribing information. National Library of Medicine.
5. Takeda Pharmaceutical Company Limited. (2024). Annual report and product information.